| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
49,370,000 |
| Market
Cap: |
16.91(M) |
| Last
Volume: |
50,736 |
Avg
Vol: |
50,595 |
| 52
Week Range: |
$0.28 - $0.64 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. Co.'s two clinical-stage product candidates are zilovertamab and ONCT-216. Co. is developing ONCT-216, an investigational small molecule that inhibits the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. In addition, Co. is developing ONCT-808, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,980 |
10,980 |
38,980 |
268,980 |
| Total Buy Value |
$95,117 |
$95,117 |
$104,941 |
$172,282 |
| Total People Bought |
2 |
2 |
3 |
7 |
| Total Buy Transactions |
4 |
4 |
6 |
14 |
| Total Shares Sold |
980 |
980 |
980 |
980 |
| Total Sell Value |
$8,859 |
$8,859 |
$8,859 |
$8,859 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Krishnan Rajesh |
Chief Technology Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
29,867 |
29,867 |
|
- |
|
| Vincent Richard G |
Chief Financial Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
29,867 |
70,662 |
|
- |
|
| Leavitt Chase C. |
General Counsel/Secretary |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
29,867 |
31,367 |
|
- |
|
| Kaufmann Gunnar F. |
Chief Scientific Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
29,867 |
29,867 |
|
- |
|
| Yazji Salim |
Chief Medical Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
57,137 |
57,137 |
|
- |
|
| Breitmeyer James B |
Chief Executive Officer |
• • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
I/I |
6,793 |
6,793 |
|
- |
|
| Breitmeyer James B |
Chief Executive Officer |
• • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
128,557 |
384,149 |
|
- |
|
| Hale David F |
Director |
– • – |
2021-06-30 |
4 |
S |
$4.75 |
$17,428 |
I/I |
(3,669) |
713,152 |
|
12% |
|
| Leavitt Chase C. |
General Counsel/Secretary |
• – – |
2021-06-11 |
4 |
B |
$5.45 |
$8,175 |
D/D |
1,500 |
1,500 |
2.74 |
-29% |
|
| Carter Michael G |
Director |
– • – |
2020-09-01 |
4 |
B |
$2.10 |
$150,001 |
D/D |
71,429 |
71,947 |
2.39 |
156% |
|
| Shanghai Pharmaceuticals (hk) Investment Ltd |
10% Owner |
– – • |
2020-07-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,049,317 |
|
15% |
|
| Kisner Daniel L |
Director |
– • – |
2020-07-21 |
4 |
B |
$2.38 |
$23,825 |
I/I |
10,000 |
10,000 |
2.1 |
15% |
|
| Aker Hazel M |
Legal Counsel |
• – – |
2020-07-21 |
4 |
B |
$2.38 |
$99,998 |
I/I |
41,972 |
46,987 |
1.99 |
15% |
|
| Shanghai Pharmaceuticals Holding Co., Ltd. |
10% Owner |
– – • |
2020-07-21 |
4 |
B |
$2.38 |
$2,499,998 |
I/I |
1,049,317 |
3,544,431 |
1.5 |
15% |
|
| Hale David F |
Director |
– • – |
2020-05-21 |
4 |
B |
$0.00 |
$0 |
I/I |
17,412 |
716,818 |
2.02 |
-42% |
|
| Hale David F |
Director |
– • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
717,752 |
18,346 |
|
- |
|
| Larue William R |
Director |
– • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
10,030 |
10,030 |
|
- |
|
| Larue William R |
Director |
– • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,144 |
16,144 |
|
- |
|
| Shanghai Pharmaceutical (usa) Inc. |
10% Owner |
– – • |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
2,495,114 |
2,495,114 |
|
- |
|
| Vincent Richard G |
Chief Financial Officer |
• – – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
6,360 |
1,834 |
|
- |
|
| Vincent Richard G |
Chief Financial Officer |
• – – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
42,628 |
40,794 |
|
- |
|
| Aker Hazel M |
General Counsel |
• – – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
5,015 |
5,015 |
|
- |
|
| Aker Hazel M |
General Counsel |
• – – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
4,284 |
4,284 |
|
- |
|
| Theuer Charles |
Director |
– • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
14,677 |
14,677 |
|
- |
|
| Breitmeyer James B |
President, CEO |
• • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
22,277 |
21,544 |
|
- |
|
189 Records found
|
|
Page 3 of 8 |
|
|
